| abstract |
Disclosed is a pharmaceutical composition useful for the treatment and prevention of arrhythmia and long QT syndrome. A pharmaceutical composition comprising l-cis-diltiazem or a salt thereof. L-cis-diltiazem, an optical isomer of d-cis-diltiazem, which is clinically used as an indication for hypertension and angina pectoris, is induced to differentiate from iPS cells derived from patients with prolonged QT syndrome having a CALCN1C gene mutation. In cardiomyocytes, voltage-dependent L-type calcium channel suppression did not occur, and the delayed inactivation process was significantly promoted. [Selection figure] None |